HC Wainwright & Co. Reiterates Buy on Apellis Pharmaceuticals, Maintains $82 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao has reiterated a 'Buy' rating on Apellis Pharmaceuticals (NASDAQ:APLS) and maintained a price target of $82.
August 07, 2023 | 10:24 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Apellis Pharmaceuticals has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $82.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates their continued confidence in Apellis Pharmaceuticals. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100